Compare DSX & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSX | NMRA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 302.0M |
| IPO Year | 2005 | 2023 |
| Metric | DSX | NMRA |
|---|---|---|
| Price | $2.39 | $1.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 601.8K | ★ 648.3K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.28 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $0.83 |
| 52 Week High | $2.92 | $3.65 |
| Indicator | DSX | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 51.79 |
| Support Level | $2.37 | $1.50 |
| Resistance Level | $2.42 | $1.72 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 55.71 | 76.00 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.